MedTrace Logo

Observational Study of Immune Response to Hepatitis B Childhood Booster

NCT00873652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2017-12-08

No results posted yet for this study

Summary

The UK immunisation guidelines recommend that children immunised with an accelerated course of hepatitis B vaccine (i.e. vaccination at 0, 1, 2 and 12 months) receive an additional booster dose of vaccine in later childhood (usually at 3 1/2 years of age). The primary objective of this study is to to assess what proportion of these children have 'protective' concentrations (10mIU/ml) of hepatitis B specific antibodies before and after the booster dose of hepatitis B vaccine.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Engerix B®, a recombinant hepatitis B vaccine

Single 0.5 ml dose intramuscularly into the deltoid muscle

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Matthew D Snape, MBBS, FRCPCH · Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford OX3 7LJ

Eligibility

Min Age
41 Months
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00873652 on ClinicalTrials.gov